HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: A randomized controlled trial

Journal of Viral Hepatitis

Volumn 21, Issue 7, 2014, Pages 458-465

  Colombatto, P ^a   Brunetto, M R ^a   Maina, A M ^a   Romagnoli, V ^a   Almasio, P ^b   Rumi, M G ^c   Ascione, A ^d   Pinzello, G ^e   Mondelli, M ^f   Muratori, L ^g   Rappuoli, R ^h   Rosa, D ^h   Houghton, M ⁱ   Abrignani, S ^j   Bonino, F ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j National Institute of Molecular Genetics (INGM)   (Italy)

more..

Author keywords

HCV; immune response; interferon; neutralizing antibodies; vaccine; viral kinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; E1E2MF59 VACCINE; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS VACCINE; IMMUNOLOGICAL ADJUVANT; MACROGOL DERIVATIVE; MF59 OIL EMULSION; POLYSORBATE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SQUALENE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; IMMUNE RESPONSE; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE WARMTH; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; BLOOD; CELL PROLIFERATION; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; HEPATITIS C, CHRONIC; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; POLYSORBATES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SQUALENE; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; VIRAL LOAD;

EID: 84902260916     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12163     Document Type: Article

References (27)

1. Choo QL, Richman KH, Han JH, et al,. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 2451-2455.
2. Bartenschlager R, Frese M, Pietschmann T,. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004; 63: 71-180.
3. Moradpour D, Penin F, Rice CM,. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
4. Weiner AJ, Brauer MJ, Rosenblatt J, et al,. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180 (2): 842-848.
5. Weiner AJ, Geysen HM, Christopherson C, et al,. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89 (8): 3468-3472.
6. Kato N, Ootsuyama Y, Sekiya H, et al,. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 1994; 68 (8): 4776-4784.
7. Brunetto MR, Suzuki T, Aizaky H, et al,. Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease. Ital J Gastroenterol 1996; 28 (9): 499-504.
8. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH,. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
9. Fattovich G, Giustifna G, Degos F, et al,. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterol 1997; 112: 463-472.
10. Kim WR, Terrault NA, Pedersen RA, et al,. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137 (5): 1680-1686.
11. Choo QL, Kuo G, Ralston R, et al,. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci 1994; 91: 1294-1298.
12. Abrignani S, Houghton M, Hsu HH,. Perspectives for a vaccine against hepatitis C virus. J Hepatol. 1999; 31 (S1): 259-263.
13. Houghton M, Abrignani S,. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961-966.
14. Hoofnagle JH,. A step forward in therapy for hepatitis C. N Engl J Med 2009; 360 (18): 1899-1901.
15. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362 (14): 1292-1303.
16. Neumann AU, Lam NP, Dahari H, et al,. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282: 103-107.
17. Colombatto P, Civitano L, Oliveri F, et al,. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003; 8 (6): 519-530.
18. Frey SE, Houghton M, Coates S, et al,. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28 (38): 6367-6373.
19. Rosa D, Campagnoli S, Moretto C, et al,. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996; 93 (5): 1759-1763.
20. Colombatto P, Ciccorossi P, Maina AM, et al,. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther 2008; 84 (2): 212-215.
21. Brunetto MR, Colombatto P, Bonino F,. Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. World J Gastroenterol 2009; 15 (5): 531-537.
22. Torresi J, Johnson D, Wedemeyer H,. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54 (6): 1273-1285.
23. Auffermann-Gretzinger S, Keeffe EB, Levy S,. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97 (10): 3171-3176.
24. Dolganiuc A, Chang S, Kodys K, et al,. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 2006; 177 (10): 6758-6768.
25. Shiina M, Rehermann B,. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008; 47 (2): 385-395.
26. Piccioli D, Tavarini S, Nuti S, et al,. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005; 42 (1): 61-67.
27. Lindh M, Lagging M, Arnholm B, et al,. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 2011; 18 (7): 325-331.